Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Hansjürgen Agostini"'
Autor:
Derek Y Kunimoto, Andrew J. Lotery, Yehia Hashad, Rahul N. Khurana, Charles C. Wykoff, Young Hee Yoon, Francesco Bandello, Werner Schmidt, Cedar, Eric H Souied, Grace Le, Jenny Jiao, David R. Chow, Andrew Chang, Xiao-yan Li, Sequoia Study Groups, Hansjürgen Agostini, Masahito Ohji, Rubens Belfort, Raj K. Maturi
Publikováno v:
Ophthalmology. 127:1331-1344
Purpose To compare the efficacy and safety of abicipar every 8 weeks and quarterly (after initial doses) versus ranibizumab every 4 weeks in treatment-naive patients with neovascular age-related macular degeneration (AMD). Design Two randomized, mult
Autor:
Hansjürgen Agostini, Young Hee Yoon, Cedar, Rahul N. Khurana, Charles C. Wykoff, David R. Chow, Raj K. Maturi, Andrew Chang, Derek Y Kunimoto, Rubens Belfort, Eric H Souied, Masahito Ohji, Francesco Bandello, Andrew J. Lotery, Kimmie Kim, Yehia Hashad, Xiao-yan Li, Jenny Jiao, Grace Le, Werner Schmidt, Sequoia Study Groups
Publikováno v:
Ophthalmology. 128(7)
To report the 2-year efficacy and safety of abicipar every 8 weeks and quarterly (after initial doses) compared with monthly ranibizumab in patients with treatment-naïve neovascular age-related macular degeneration (nAMD).Two multicenter, randomized
Autor:
Günther Schlunck, Andreas Stahl, Hansjürgen Agostini, Bertan Cakir, Franziska Fischer, Daniel Böhringer, Christoph Ehlken, Anima Bühler, Clemens Lange
Publikováno v:
Graefe's Archive for Clinical and Experimental Ophthalmology. 254:2151-2157
Chronic central serous chorioretinopathy (CSC) is a vision-threatening eye disease for which there is still no approved treatment. Recent studies suggest that the corticosteroid pathway in the choroid is implicated in CSC pathogenesis, and that thera
Autor:
Hansjürgen Agostini, Christoph Ehlken, Ulrike Bauer-Steinhusen, Zoran Hasanbasic, Thomas Wilke, Sabrina Mueller
Publikováno v:
Ophthalmology. 123:876-883
Purpose The objective of our study was to investigate preferences of patients with neovascular age-related macular degeneration (nAMD) for different anti-vascular endothelial growth factor (VEGF) treatment schemes. Design We used a discrete choice ex
Autor:
Birgit Muntau, Hansjürgen Agostini, Bernd Junker, Sven Poppert, Moritz Fritzenwanker, Martin Heideking, Jürgen Krücken, Philipp Henneke, Markus Hufnagel, Nicole Wüppenhorst, Winfried V. Kern
Publikováno v:
Emerging Infectious Diseases
Emerging Infectious Diseases, Vol 23, Iss 2, Pp 343-344 (2017)
Emerging Infectious Diseases, Vol 23, Iss 2, Pp 343-344 (2017)
Diffuse unilateral subacute neuroretinitis is an ocular infectious disease caused by several distinct nematodes. Definite identification of the involved nematodes is rarely achieved. We report on the molecular-based genetic identification of an Ancyl
Autor:
Bernd Junker, Nicolas Feltgen, Armin Buchwald, Lois E.H. Smith, Jing Chen, Gottfried Martin, Lutz L. Hansen, Andreas Stahl, Hansjürgen Agostini
Publikováno v:
Retina. 30:1524-1529
Retinal vein occlusion (RVO) is one of the most frequently occurring retinal vascular disorders. Occlusion of either the central retinal vein or one of its branches leads to disruption of retinal blood flow and subsequent tissue hypoxia. The disease
Publikováno v:
European Journal of Ophthalmology. 20:180-185
Purpose Bevacizumab (Avastin®) was first used clinically in 2005. Reports on the treatment of more than 600 patients with central retinal vein occlusion (CRVO) have been published to date. However, there are limited data on the long-term effects of
Autor:
Hansjürgen Agostini, Focke Ziemssen
Publikováno v:
Ophthalmology. 122:e20-e21
Autor:
Hansjürgen Agostini, S Jungmann, Bernd Junker, Christoph Ehlken, Daniel Böhringer, Amelie Pielen
Publikováno v:
Eye (London, England). 28(5)
Although anti-VEGF therapy of exudative AMD with bevacizumab and ranibizumab proved efficacious in the majority of patients, CNV activity does not respond to continued treatment after repeated injections in a considerable amount of patients. These ar
Publikováno v:
Archives of ophthalmology (Chicago, Ill. : 1960). 130(9)